AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2021
Jul 2, 2021
32883_dirs_2021-07-02_532272d2-04de-4fcb-843b-ddada57a3f35.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2021-06-30
Reporting Person: Cittadine Andrew (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-30 | Stock Options | $5.890 | A | 30000 | Acquired | 2031-05-31 | Common Stock (30000) | Direct |
Footnotes
F1: Options vest 6/48ths on November 30, 2021 and 1/48th monthly on the last day of each month thereafter.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2